 |
belatacept |
|---|---|
| Trade Name | Nulojix |
| Orphan Indication | Prophylaxis of organ rejection in renal allograft recipients |
| USA Market Approval | USA |
| USA Designation Date | 2008-02-20 00:00:00 |
| Sponsor | Bristol-Myers Squibb Company;P. O. Box 4000;Princeton, New Jersey, 08543 |
